Market research
NKTR Nektar Therapeutics
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 144.4
- Dividend yield
- Not available
- Beta
- 1.16
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6402683063
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 144.4
- Dividend yield
- Not available
- Beta
- 1.16
About
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NKTR discussion.
5 years, 4 months ago
Nektar Therapeutics is currently in a long term downtrend where the price is trading 9.7% below its 200 day moving average.
From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.8.
Nektar Therapeutics's total revenue sank by 30.7% to $23M since the same quarter in the previous year.
Its net income has dropped by 3.3% to $-117M since the same quarter in the previous year.
Finally, its free cash flow grew by 22.1% to $-100M since the same quarter in the previous year.
Based on the above factors, Nektar Therapeutics gets an overall score of 2/5.